Changes in antibiotic resistance level of nosocomial Pseudomonas aeruginosa isolates in the largest University Hospital of Lithuania

Medicina

Volumn 47, Issue 5, 2011, Pages 278-283

  Adukauskiene, Dalia ^a   Vitkauskaite, Agne ^a   Skrodeniene, Erika ^a   Dambrauskiene, Asta ^a   Vitkauskiene, Astra ^a  

^a LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

Author keywords

Minimum inhibitory concentration; Multidrug resistance; Resistance level of Pseudomonas aeruginosa to antibiotics

Indexed keywords

ANTIBIOTIC RESISTANCE; ARTICLE; CROSS INFECTION; DRUG EFFECT; HUMAN; ISOLATION AND PURIFICATION; LITHUANIA; MICROBIOLOGY; PHYSIOLOGY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; UNIVERSITY HOSPITAL;

CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; HOSPITALS, UNIVERSITY; HUMANS; LITHUANIA; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 80053294747     PISSN: 00257729     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Van Eldere J. Multicentre surveillance of Pseudomonas aeruginosa susceptibility patterns in nosocomial infections. J Antimicrob Chemother 2003;51:347-52.
2. Pollini S, Fiscarelli E, Mugnaioli C, Di Pilato V, Ricciotti G, Neri AS, et al. Pseudomonas aeruginosa infection in cystic fibrosis caused by an epidemic metallo-β-lactamaseproducing clone with a heterogeneous carbapenem resistance phenotype. Clin Microbiol Infect 2011;17(8):1272-5.
3. Zavascki AP, Barth AL, Fernandez JF, Didonet Moro AL, Saraiva Goncalves AL, Gordani LZ. Pseudomonas aeruginosa hospital-acquired pneumonia mortality in the era of metallo-β-lactamase-mediated multidrug resistance: a pro-spective observational study. Critical Care 2006;10:R114.
4. Ferrer R, Martinez ML, Valles J. Time to onset of ventilator-associated pneumonia and influence on mortality. Int J Intensive Care 2008;15(2):52-5.
5. Vitkauskienė A, Skrodenienė E, Dambrauskienė A, Macas A, Sakalauskas R. Pseudomonas aeruginosa bacteremia: resistance to antibiotics, risk factors, and patient prognosis. Medicina (Kaunas) 2010;46(7):490-5.
6. Soo Hoo W, Wen EY, Nguyen TV, Goetz MB. Impact of clinical guidelines in the management of severe hospitalacquired pneumonia. Chest 2005;128:2778-87.
7. Kollef MH. Appropriate empiric antimicrobial therapy of nosocomial pneumonia: the role of the carbapenems. Resp Care 2004;49:12.
8. Micek ST, Lloyd AE, Ritchie DJ, Reichley RM, Fraser VJ, Kollef MH. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005;49:1306-11.
9. Torres A, Ferrer M, Badia JR. Treatment guidelines and out comes of hospital-acquired and ventilator-associated pneumonia. Clin Infect Dis 2010;51(Suppl 1):S48-53.
10. Reynolds R, Potz N, Colman M, Williams A, Livermore D, MacGowan A. Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: the BSAC Bacteraemia Resistance Surveillance Programme. J Antimicrob Chemother 2004;53(6):1018-32.
11. Moine P, Timsit JF, De Lassence A, Troche G, Fosse JP, Alberti C, et al. Mortality associated with late-onset pneumonia in the intensive care unit: results of multi-center cohort study. Intensive Care Med 2002;28:154-63.
12. Villegas MV, Quinn JP. An update on antibiotic-resistant gram-negative bacteria. Infect Med 2004;21:595-9.
13. Dambrauskienė A, Adukauskienė D, Jeroch J, Vitkauskienė A. Pseudomonas aeruginosa bacteremia: associations with a source of infection and antibiotic resistance. Medicina (Kaunas) 2009;45(1):1-7.
14. Giantsou E, Liratzopuolos N, Efraimidou E, Panopoulou M, Alepopoulou E, Kartali- Ktenidou S, et al. Both earlyonset and late-onset ventilator-associated pneumonia are caused mainly by potentially multiresistant bacteria. Intensive Care Med 2005;31:1488-94.
15. Lodise TP, Miller CD, Graves J, Furuno JP, McGregor JC, Lomaestro B, et al. Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance. Antimicrob Agents Chemother 2007;51(2):417-22.
16. Bronzwaer SL, Cars O, Buchholz U, Molstad S, Goettsch W, Veldhuijzen IK, et al. A European study on the relationship between antimicrobial use and antimicrobial resistance. Emerg Infect Dis 2002;8:278-82.
17. Rossolini GM, Mantengoli E. Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. Clin Microbiol Infect 2005;11 Suppl 4:17-32.
18. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility test. Approved standard M2-M9. National Committee for Clinical Laboratory Standards; 9th ed. 2008. Available from: URL: http://www.clsi.org
19. Sofianou D, Tsakris A, Skoura L, Douboyas J. Extended high-level cross-resistance to antipseudomonal antibiotics amongst Pseudomonas aeruginosa isolates in a university hospital. J Antimicrob Chemother 1997;40:740-2.
20. Minchella A, Molinari L, Alonso S, Bouziges N, Sotto A, Lavigne JP. Evolution of antimicrobial resistance against Pseudomonas aeruginosa in a French university hospital between 2002 and 2006. Pathol Biol 2010;58(1):1-6.
21. Stratcheunski LS, Kozlov RS, Rechedko GK, Stetsiouk OU, Chavrikova EP. Antimicrobial resistance patterns among aerobic gram-negative bacilli isolated from patients in intensive care units: results of a multicenter study in Russia. Clin Microbiol Infect 1998;4:497-507.
22. Bonfiglio G, Carciotto V, Russo G, Stefani S, Schito GC, Debbia E, et al. Antibiotic resistance in Pseudomonas aeruginosa: an Italian survey. J Antimicrob Chemother 1998;41:307-10.
23. Bouza E, Garcia-Garrote F, Cercenado E, Marin M, Diaz MS. Pseudomonas aeruginosa: a survey of resistance in 136 hospitals in Spain. The Spanish Pseudomonas aeruginosa Study Group. Antimicrob Agents Chemother 1999;43:981-2.
24. Mutnick AH, Rhomberg PR, Sader HS, Jones RN. Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001). J Antimicrob Chemother 2004;53(2):290-6.
25. De Champs C, Poirel L, Bonnet R, Sirot D, Chanal C, Sirot J, et al. Prospective survey of beta-lactamases produced by ceftazidime-resistant Pseudomonas aeruginosa isolated in a French hospital in 2000. Antimicrob Agents Chemother 2002;46:3031-4.
26. Gould IM. Clinical relevance of increasing glycopeptide MICs against Staphylococcus aureus. Antimicrobial Agents 2008;31:1-9.
27. Dimatatac EL, Alejandria MM, Montalban C, Pineda C, Ang C, Delino RL. Clinical outcomes and costs of care of antibiotic resistant Pseudomonas aeruginosa infections. Phil J Microbiol Infect Dis 2003;32:159-67.
28. Wu YL, Scott EM, Po AL, Tariq VN. Development of resistance and cross-resistance in Pseudomonas aeruginosa exposed to subinhibitory antibiotic concentrations. APMIS 1999;107:585-92.
29. Karlowsky JA, Draghi DC, Jones ME, Thornsberry C, Friedland IR, Sahm DF. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob Agents Chemother 2003;47:1681-8.
30. Kaye KS, Kanafani ZA, Dodds AE, Engemann JJ, Weber SG, Carmeli Y. Differential effects of levofloxacin and ciprofloxacin on the risk for isolation of quinolone-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006;50:2192-6.
31. Loeffler JM, Garbino J, Lew D, Harbarth S, Rohner P. Antibiotic consumption, bacterial resistance and their correlation in a Swiss university hospital and its adult intensive care units. Scand J Infect Dis 2003;35:843-50.
32. Iosifidis E, Antachopoulos C, Tsivitanidou M, Katragkou A, Farmaki E, Tsiakou M, et al. Differential correlation between rates of antimicrobial drug consumption and prevalence of antimicrobial resistance in tertiary care hospital in Greece. Infect Control Hosp Epidemiol 2008;29(7):615-22.